The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome - Trial NCT06328166
Access comprehensive clinical trial information for NCT06328166 through Pure Global AI's free database. This phase not specified trial is sponsored by Tri-Service General Hospital and is currently Not yet recruiting. The study focuses on Carpal Tunnel Syndrome. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tri-Service General Hospital
Timeline & Enrollment
N/A
Mar 22, 2024
Dec 31, 2024
Primary Outcome
Change from baseline of severity of symptoms and functional status on 1st month, 2nd month, 3rd month,4th month, 6th month after injection.
Summary
Carpal tunnel syndrome (CTS) is a common peripheral entrapment mononeuropathy of the upper
 limb, which results from compression of median nerve at level of wrist. In recent years,
 regenerative medicine has gradually been applied in the treatment of various degenerative
 conditions such as bones, muscles, and nerves. Human fibroblast growth factor 1 is a
 single-chain protein , which has been shown to play a crucial regulatory role in the brain
 and spinal cord and can facilitate nerve cell differentiation and growth. ES135 is a
 recombinant human fibroblast growth factor 1 (rhFGF1) which is composed of 135 amino acids
 with a molecular weight of approximately 15.2 kilodalton. Several studies have shown that
 significant improvement of Functional Independence Measure, motor and sensory function of
 spinal cord injury patients after ES135 treatment. One study also revealed the muscle
 strength have significant improvement in brachial plexus injury patients after ES135 therapy.
 According to above studies, the investigators hypothesized that ES135 may have benefits to
 CTS patients. Hence, the purpose of this study aim to demonstrate the therapeutic effects and
 safety of ES135 for CTS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06328166
Non-Device Trial